Join our Community
Support ToI and remove all ads
Learn more
×

RedHill Biopharma

Clalit Health care workers take test samples of Israelis to check if they have been infected with the coronavirus, in a testing center in Modiin Illit, on September 7, 2020. (Yossi Aloni/FLASH90)
September 8, 2020, 7:04 pm
RedHill says in-vitro study shows drug is ‘potent’ inhibitor of coronavirus
Opaganib ‘completely inhibited’ replication of the SARS-CoV-2 virus in in-vitro model of human bronchial tissue, Israeli firm says; study still to be submitted for peer review
By Shoshanna Solomon
Illustrative: An elderly patient is treated for coronavirus (iStock)
August 24, 2020, 11:33 am
Israel’s RedHill hopes dual-action drug can be ‘game changer’ in COVID-19 battle
Compassionate and experimental use of Opaganib in Israel has had ‘encouraging results’; by inhibiting enzyme, drug helps reduce inflammation levels and halts virus from replicating
By Shoshanna Solomon
Medical workers treat a COVID-19 patient at the coronavirus unit in Mayanei Hayeshua Medical Center, Bnei Brak, April 13, 2020. (Nati Shohat/Flash90)
April 13, 2020, 6:34 pm
2 Israeli COVID-19 patients said to improve in experimental drug trial
Pair treated with Opaganib, from biopharmaceutical firm RedHill, showed progress within a few days of starting treatment, company says
By Luke Tress
Magen David Adom workers wearing protective clothing, as a preventive measure against the coronavirus evacuate a suspected coronavirus patient to the new coronavirus unit at Shaare Zedek Medical Center, in Jerusalem on April 3, 2020. (Nati Shohat/Flash90)
April 6, 2020, 11:33 pm
Israel’s Redhill Biopharma gets green light for experimental COVID-19 treatment
Firm’s Opaganib drug administered to coronavirus patient for the first time in Israel, gets approval from Italian authorities under compassionate use guidelines
By Luke Tress
Illustrative A nurse in a hospital, in Israel, on September 3, 2017. (Hadas Parush/Flash90)
March 10, 2020, 1:36 pm
Israel’s Redhill Biopharma launches US sales of anti-bacterial drug
Firm’s Talicia pill combats H. pylori bacteria, a major carcinogen which affects some 2 million US adults
By Luke Tress
RedHill's RHB-105 or Talicia drug for H. pylori. (Courtesy)
November 4, 2019, 3:12 pm
RedHill gets FDA nod for drug to eradicate gut infection
Israeli firm plans to start selling the pill in the US in first quarter 2020, targeting more than 2 million patients treated for H. pylori infection annually; shares surge
By Shoshanna Solomon
RedHill's RHB-105 or Talicia drug for H. pylori. (Courtesy)
May 7, 2019, 2:53 pm
RedHill seeks FDA nod for drug to eradicate gut infection
If the Talicia drug to combat H. pylori bacterial infection gets approved, commercial launch is planned for the fourth quarter of 2019, Israeli firm says
By Shoshanna Solomon
RedHill's RHB-105 or Talicia drug for H. pylori. (Courtesy)
December 3, 2018, 5:58 pm
Israel’s RedHill says drug shown effective in eradicating gut infection
Biotech firm’s Talicia drug was found in a late-stage study to vanquish H. pylori in 84% of patients; the bacteria can cause ulcers and gastric cancer
By Shoshanna Solomon
Illustrative. (Bet_Noire; iStock by Getty Images)
October 24, 2018, 11:59 am
RedHill gets added backwind for drug to treat Crohn’s disease
Israeli biopharmaceutical firm is also awaiting results of critical study on its drug to combat H. pylory, the bacteria that can cause peptic ulcer and gastric cancer
By Shoshanna Solomon
Illustrative image of a stomachache (ake1150sb; iStock by Getty Images)
July 30, 2018, 4:09 pm
RedHill’s drug for Crohn’s disease shows positive results – study
Findings indicate that RHB-104, developed by the Israeli biopharmaceutical firm, could lead to a ‘paradigm shift’ in treatment of the gastrointestinal disease
By Shoshanna Solomon
The Nasdaq building in Times Square in New York. (littleny, iStock by Getty Images)
From the WebJuly 24, 2018, 1:08 pm
Gastro treatment firm RedHill wants to raise $117 on Nasdaq
Calcalist: RedHill’s treatment for Crohn’s disease is currently in phase 3 trials; results of the trial are expected in coming weeks
Gamida Cell's lab in Jerusalem, where umbilical cord blood is stored in tanks (Shoshanna Solomon/Times of Israel)
August 17, 2017, 12:44 pm
Coming of age, Israel biotech sector gets ready for market
After billion-dollar NeuroDerm sale, life science firms Gamida Cell, BiondVax, RedHill and Vascular Biogenics are gearing up for commercialization
By Shoshanna Solomon
Illustrative photo of pharmaceutical pills. (Abed Rahim Khatib/Flash90)
June 14, 2017, 4:27 pm
Israel’s RedHill says gastroenteritis drug found safe in study
In Phase III GUARD study, Bekinda in 24 mg was found to be efficacious and well-tolerated, biotech firm says
By Shoshanna Solomon
The red hill seen from Kibbutz Givat Brenner that inspired the name of biotech company RedHill (Courtesy)
April 13, 2017, 12:29 pm
Kibbutz duo-turned-entrepreneurs on quest to whip gut bugs
Israeli biotech firm RedHill is conducting late-stage clinical trials to tackle Crohn’s disease and the ulcer-generating H. pylori bacteria
By Shoshanna Solomon
RedHill CEO Dror Ben Asher (Screenshot)
June 15, 2015, 6:59 pm
Israeli ulcer-preventing drug shows top results in study
H. pylori, a principal cause of ulcers and even gastric cancer, has met its match in RedHill Biopharma’s RHB-105 treatment
By David Shamah
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.